The pharmacoeconomics of respiratory tract infections

Clinical Pulmonary Medicine

Volumn 3, Issue 6, 1996, Pages 323-328

  Paul, Oh ^a   Mclvor, Andrew ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cost effectiveness analysis; Pharmacoeconomics; Respiratory infections

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; QUINOLONE DERIVATIVE; TETRACYCLIC ANTIDEPRESSANT AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MEDICAL DECISION MAKING; PRESCRIPTION; RESPIRATORY TRACT INFECTION; TREATMENT PLANNING;

EID: 0030442710     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045413-199611000-00004     Document Type: Article

References (4)

1. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78:45-51.
2. Rosenblatt RA, Gherkin DC, Schneeweiss R, Hart LG. The content of ambulatory medical care in the United States: an interspecialty comparison. N Engl J Med 1993;309:892-7.
3. Townsend TR, Shapiro M, Rosner B, Kass EH. Use of antimicrobial drugs in general hospitals. I. Description of population and definition of methods. J Infect Dis 1979;139: 688-97.
4. The Canadian community acquired pneumonia consensus conference group. Antimicrobial treatment of community acquired pneumonia in adults: a conference report. Can J Infect Dis 1993;4:25-8.